Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck

NCT01884259 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.

NCT NCT01884259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01884259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
January 13, 2022
Enrollment
100 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the hypopharynx stage iii, squamous cell carcinoma of the hypopharynx stage iv, squamous cell carcinoma of the larynx stage iii, squamous cell carcinoma of the larynx stage iv, squamous cell carcinoma of the oral cavity stage iii, squamous cell carcinoma of the oral cavity stage iv, squamous cell carcinoma of the oropharynx stage iii, squamous cell carcinoma of the oropharynx stage iv